Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
about
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsIL15 and T-cell Stemness in T-cell-Based Cancer ImmunotherapyIL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity.Common gamma chain cytokines in combinatorial immune strategies against cancerExceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma.Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposureA folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy.Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Innate immune mediators in cancer: between defense and resistance.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.High-density lipoproteins delivering interleukin-15.The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain.Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.The potential and promise of IL-15 in immuno-oncogenic therapies.
P2860
Q26774903-3BD5308A-885C-4978-9AFE-56BAC2E7345FQ28088543-3A1F367C-60A0-4297-8D59-EF7C148AD40CQ36060253-A26FD8E2-1779-44A5-9718-2E9D76C29865Q36455872-5079B94A-1423-4752-9BE9-F89565702A1FQ37086138-E761288A-D930-40A9-8BEE-8758D2C224C4Q37580158-CDA0FB74-5BBA-4AD0-B912-D94D0BB54016Q37588429-C774DD7B-B4E8-4B7F-AE73-ED8B105F46F0Q38099680-DD3D9B21-74B7-4DF7-B629-E341F6E36B7CQ38991015-4A0381E9-1808-4BEB-993E-8FD1B26596E3Q39110347-521A07ED-8604-41A1-AF15-703A94459BCDQ40049630-7D32E38B-DCEF-4FD4-9B52-685E1B6CB344Q40724784-8B7FEFD5-A4A3-4C12-B053-D8D60F70448CQ41684097-E11A6335-0399-4E0E-9ABF-7E801B21B315Q42751492-6E85C407-C5EE-48C3-9E64-1BFF0F6A7EB5Q47225780-840B5807-9661-48B9-AEAD-1A37242C2865Q49216382-F03F4056-F527-44E7-B707-9108E50CD0EA
P2860
Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein.
@en
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein.
@nl
type
label
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein.
@en
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein.
@nl
prefLabel
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein.
@en
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein.
@nl
P2093
P50
P1433
P1476
Antitumor immunotherapeutic an ...... chimeric IL-15 fusion protein
@en
P2093
Alfonso Gúrpide
Arantza Azpilikueta
Guillermo Mazzolini
Ignacio Melero
Inmaculada Rodriguez
Pedro Berraondo
P304
P356
10.1158/0008-5472.CAN-12-2660
P407
P577
2012-11-13T00:00:00Z